LICENSE AGREEMENTS (Details) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2012	Jan. 31, 2012	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2012	Jun. 30, 2022	Jun. 22, 2014
Maximum [Member]
Liquidity and Capital Resources
Term of license		15 years
BRIUMVI (Ublituximab)
Liquidity and Capital Resources
Upfront fee	$ 2,000,000.0					$ 2,000,000
Income taxes	$ 300,000
Revenue				$ 76,000
Term after first commercial sale	15 years
Deferred Revenue			$ 400,000	400,000	$ 500,000
License revenue			38,000	38,000			$ 38,000
Deferred Revenue, Current			200,000	200,000
Expenses incurred				31,000,000.0
Royalty Expense			1,500,000	2,300,000
Royalty payable			1,500,000	1,500,000
BRIUMVI (Ublituximab) | Maximum [Member]
Liquidity and Capital Resources
Additional payments on achievement of certain milestones		$ 12,000,000.0
Potential milestones payable			5,000,000.0	5,000,000.0
UKONIQ (umbralisib) [Member]
Liquidity and Capital Resources
Expenses incurred				24,000,000.0
Potential milestones payable								$ 175,000,000
Accrued Royalties			$ 0	$ 0
Royalty Expense					200,000
Royalty payable					$ 3,000